• Je něco špatně v tomto záznamu ?

Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific Outcomes

C. Madeira, L. Hořavová, F. Dos Santos, JR. Batuca, K. Nebeska, L. Součková, C. Kubiak, J. Demotes, R. Demlová, EC. Monteiro

. 2021 ; 55 (5) : 966-978. [pub] 20210518

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025068

Grantová podpora
CZECRIN_4 PACIENTY (No. CZ.02.1.01/0.0/0.0/16_013/0001826) European Regional Development Fund
CZECRIN - LM2015090 Large Research infrastructure
Portaria no 237/2014 Fundação para a Ciência e a Tecnologia

OBJECTIVES: Clinical trials provide one of the highest levels of evidence to support medical practice. Investigator initiated clinical trials (IICTs) answer relevant questions in clinical practice that may not be addressed by industry. For the first time, two European Countries are compared in terms of IICTs, respective funders and publications, envisaging to inspire others to use similar indicators to assess clinical research outcomes. METHODS: A retrospective systematic search of registered IICTs from 2004 to 2017, using four clinical trials registries was carried out in two European countries with similar population, GDP, HDI and medical schools but with different governmental models to fund clinical research. Each IICT was screened for sponsors, funders, type of intervention and associated publications, once completed. RESULTS: IICTs involving the Czech Republic and Portugal were n = 439 (42% with hospitals as sponsors) and n = 328 (47% with universities as sponsors), respectively. The Czech Republic and Portuguese funding agencies supported respectively 61 and 27 IICTs. Among these, trials with medicinal products represent 52% in Czech Republic and 4% in Portugal. In the first, a higher percentage of IICTs' publications in high impact factor journals with national investigators as authors was observed, when compared to Portugal (75% vs 15%). CONCLUSION: The better performance in clinical research by Czech Republic might be related to the existence of specific and periodic funding for clinical research, although further data are still needed to confirm this relationship. In upcoming years, the indicators used herein might be useful to tracking clinical research outcomes in these and other European countries.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025068
003      
CZ-PrNML
005      
20240206144725.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s43441-021-00293-w $2 doi
035    __
$a (PubMed)34003473
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Madeira, C $u European Clinical Research Infrastructure Network (ECRIN), Paris, France $u Portuguese Clinical Research Infrastructure Network (PtCRIN), Lisbon, Portugal $u Chronic Diseases Research Centre (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal $u Comprehensive Health Research Centre (CHRC), Lisbon, Portugal
245    10
$a Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific Outcomes / $c C. Madeira, L. Hořavová, F. Dos Santos, JR. Batuca, K. Nebeska, L. Součková, C. Kubiak, J. Demotes, R. Demlová, EC. Monteiro
520    9_
$a OBJECTIVES: Clinical trials provide one of the highest levels of evidence to support medical practice. Investigator initiated clinical trials (IICTs) answer relevant questions in clinical practice that may not be addressed by industry. For the first time, two European Countries are compared in terms of IICTs, respective funders and publications, envisaging to inspire others to use similar indicators to assess clinical research outcomes. METHODS: A retrospective systematic search of registered IICTs from 2004 to 2017, using four clinical trials registries was carried out in two European countries with similar population, GDP, HDI and medical schools but with different governmental models to fund clinical research. Each IICT was screened for sponsors, funders, type of intervention and associated publications, once completed. RESULTS: IICTs involving the Czech Republic and Portugal were n = 439 (42% with hospitals as sponsors) and n = 328 (47% with universities as sponsors), respectively. The Czech Republic and Portuguese funding agencies supported respectively 61 and 27 IICTs. Among these, trials with medicinal products represent 52% in Czech Republic and 4% in Portugal. In the first, a higher percentage of IICTs' publications in high impact factor journals with national investigators as authors was observed, when compared to Portugal (75% vs 15%). CONCLUSION: The better performance in clinical research by Czech Republic might be related to the existence of specific and periodic funding for clinical research, although further data are still needed to confirm this relationship. In upcoming years, the indicators used herein might be useful to tracking clinical research outcomes in these and other European countries.
650    _2
$a lidé $7 D006801
650    12
$a postup $7 D057766
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
651    _2
$a Česká republika $7 D018153
651    _2
$a Portugalsko $7 D011174
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hořavová, L $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Applied Pharmacy, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic
700    1_
$a Dos Santos, F $u Portuguese Clinical Research Infrastructure Network (PtCRIN), Lisbon, Portugal
700    1_
$a Batuca, J R $u European Clinical Research Infrastructure Network (ECRIN), Paris, France $u Portuguese Clinical Research Infrastructure Network (PtCRIN), Lisbon, Portugal $u Chronic Diseases Research Centre (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal
700    1_
$a Nebeska, K $u European Clinical Research Infrastructure Network (ECRIN), Paris, France $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Součková, Lenka $u European Clinical Research Infrastructure Network (ECRIN), Paris, France $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u University Hospital St. Anne's Brno - International Clinical Research Centre, Brno, Czech Republic $u Department of Clinical Trials, Masaryk Memorial Cancer Institute Brno, Brno, Czech Republic $7 xx0204153
700    1_
$a Kubiak, C $u European Clinical Research Infrastructure Network (ECRIN), Paris, France
700    1_
$a Demotes, J $u European Clinical Research Infrastructure Network (ECRIN), Paris, France
700    1_
$a Demlová, R $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u University Hospital St. Anne's Brno - International Clinical Research Centre, Brno, Czech Republic $u Department of Clinical Trials, Masaryk Memorial Cancer Institute Brno, Brno, Czech Republic
700    1_
$a Monteiro, E C $u Portuguese Clinical Research Infrastructure Network (PtCRIN), Lisbon, Portugal. emilia.monteiro@nms.unl.pt $u Chronic Diseases Research Centre (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal. emilia.monteiro@nms.unl.pt
773    0_
$w MED00198808 $t Therapeutic innovation & regulatory science $x 2168-4804 $g Roč. 55, č. 5 (2021), s. 966-978
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34003473 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20240206144722 $b ABA008
999    __
$a ok $b bmc $g 1714221 $s 1145575
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 55 $c 5 $d 966-978 $e 20210518 $i 2168-4804 $m Therapeutic innovation & regulatory science $n Ther Innov Regul Sci $x MED00198808
GRA    __
$a CZECRIN_4 PACIENTY (No. CZ.02.1.01/0.0/0.0/16_013/0001826) $p European Regional Development Fund
GRA    __
$a CZECRIN - LM2015090 $p Large Research infrastructure
GRA    __
$a Portaria no 237/2014 $p Fundação para a Ciência e a Tecnologia
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace